Atara Biotherapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	151.93	128.94	8.57	63.57	20.34	-
Revenue Growth (YoY)	51.27%	1404.02%	-86.52%	212.55%	-	-
Cost of Revenue	80.88	168.74	228.05	269.99	282	244.65
Gross Profit	71.05	-39.8	-219.48	-206.42	-261.66	-244.65
Selling, General & Admin	28.36	38.53	49.8	68.13	78.8	64.4
Operating Expenses	28.36	38.53	49.8	68.13	78.8	64.4
Operating Income	42.69	-78.33	-269.28	-274.55	-340.46	-309.05
Interest Expense	-3.92	-4.62	-5.29	-0.37	-	-
Interest & Investment Income	1.18	2.11	5.43	3.06	2.14	3.28
Other Non Operating Income (Expenses)	-0.07	0.53	-0.25	-0.7	-	-
EBT Excluding Unusual Items	39.88	-80.31	-269.38	-272.56	-338.33	-305.78
Merger & Restructuring Charges	-16.46	-5.11	-6.73	-5.96	-	-
Gain (Loss) on Sale of Investments	-	-	-	-	-1.77	-0.83
Gain (Loss) on Sale of Assets	-0	-	-	50.24	-	-
Pretax Income	23.41	-85.42	-276.11	-228.29	-340.1	-306.61
Income Tax Expense	0.01	-0.01	0.02	0.01	0.05	0.02
Net Income	23.4	-85.4	-276.13	-228.3	-340.14	-306.62
Net Income to Common	23.4	-85.4	-276.13	-228.3	-340.14	-306.62
Shares Outstanding (Basic)	12	7	4	4	4	3
Shares Outstanding (Diluted)	12	7	4	4	4	3
Shares Change (YoY)	102.28%	76.77%	3.83%	8.88%	26.63%	44.17%
EPS (Basic)	1.98	-11.41	-65.19	-55.96	-90.78	-103.63
EPS (Diluted)	1.97	-11.41	-65.19	-55.96	-90.78	-103.63
Free Cash Flow	-69.8	-68.96	-194.2	-274.62	-231.1	-185.27
Free Cash Flow Per Share	-5.86	-9.21	-45.84	-67.32	-61.68	-62.62
Gross Margin	46.76%	-30.87%	-	-	-	-
Operating Margin	28.09%	-60.75%	-3140.98%	-431.86%	-1673.85%	-
Profit Margin	15.40%	-66.23%	-3220.88%	-359.12%	-1672.28%	-
Free Cash Flow Margin	-45.95%	-53.49%	-2265.25%	-431.98%	-1136.19%	-
EBITDA	44.85	-73.28	-264.45	-268.9	-331.12	-300.72
EBITDA Margin	29.52%	-56.83%	-	-	-	-
D&A For EBITDA	2.17	5.05	4.83	5.65	9.35	8.33
EBIT	42.69	-78.33	-269.28	-274.55	-340.46	-309.05
EBIT Margin	28.09%	-60.75%	-	-	-	-
Revenue as Reported	128.94	128.94	8.57	63.57	-	-

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q